GSK and CAMP4 Partner to Advance RNA-Targeting Therapeutics

In a strategic move to bolster its oligonucleotide pipeline, GSK has entered into a research and license agreement with CAMP4 Therapeutics to identify and develop novel antisense oligonucleotide (ASO) candidates (1). The collaboration centers on addressing diseases driven by protein under-expression, specifically focusing on multiple gene targets within the neurodegenerative and kidney disease landscapes.

How will the partnership help advance gene upregulation?

The technical core of this partnership is CAMP4’s proprietary RAP Platform®, which is designed to map and target regulatory RNAs (regRNAs) (1). Unlike traditional ASO approaches that often focus on gene silencing, CAMP4’s platform identifies regRNAs that act as "master regulators" by working locally on transcription factors to control gene expression.

By targeting these regRNAs, the generated ASO candidates can amplify mRNA production and restore healthy protein levels (1). This approach is particularly relevant for treating more than 1,200 haploinsufficient and recessive partial loss-of-function disorders, with which even a modest increase in protein expression can result in a clinically meaningful outcome.

Are strategic alliances and scale-up current trends in biopharma?

The collaboration follows a trend of strategic alliances and technology integration seen across the biopharma landscape in late 2025 (2-4). Under the terms of the agreement (1):

• CAMP4 will utilize its platform to identify regRNAs and generate regRNA-targeting ASO candidates.

• GSK will leverage its expertise in therapeutic oligonucleotides, genetics, and advanced data technologies to manage the further development and commercialization of the identified candidates.

• CAMP4 receives a $17.5 million upfront cash payment and is eligible for future milestone-based payments and tiered royalties.

How is cutting-edge discovery integrated with manufacturing expertise?

This partnership underscores the industry’s increasing reliance on precision analytics and specialized discovery platforms to fuel the next generation of medicines. By combining CAMP4’s ability to "tune" specific gene activity with GSK’s large-scale development and manufacturing capabilities, the collaboration aims to overcome historical challenges in treating complex genetic diseases (1).

This deal aligns with broader 2025 industry shifts toward accelerating advanced next-gen therapy development through high-tech partnerships that bridge the gap between niche discovery and global scale.

References

1. CAMP4. CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries. Press Release. Dec 18, 2025.
2. Novartis. Novartis Agrees to Acquire Avidity Biosciences, an Innovator in RNA Therapeutics, Strengthening its Late-stage Neuroscience Pipeline. Press Release. Oct 26, 2025.
3. BioNTech. BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V. Press Release. Oct 22, 2025.
4. Pfizer. Pfizer Completes Acquisition of Metsera. Press Release. Nov 13, 2025.